Delving into the Latest Updates on TMV-018 with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

Target

CDA

Mechanism

CDA modulators(Cytidine deaminase modulators)

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Gastrointestinal Neoplasms

Inactive Indication-

Originator Organization

Themis Bioscience GmbH

Active Organization

Themis Bioscience GmbH

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.

Start Date23 Nov 2020

Sponsor / Collaborator

Themis Bioscience GmbH

[+2]

EUCTR2019-003550-88-DE / Not yet recruitingPhase 1/2

Full title of the trial: A Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intra-tumoral application of TMV-018 in combination with 5-Fluorocytosine or anti-PD-1 therapy in patients with tumors. - TMV-018-101

Start Date03 Jul 2020

Sponsor / Collaborator

Themis Bioscience GmbH

100 Clinical Results associated with TMV-018

Login to view more data

100 Translational Medicine associated with TMV-018

Login to view more data

100 Patents (Medical) associated with TMV-018

Login to view more data

100 Deals associated with TMV-018

Login to view more data